These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 20393344)

  • 1. Metabolic modulation: a new therapeutic target in treatment of heart failure.
    Palaniswamy C; Mellana WM; Selvaraj DR; Mohan D
    Am J Ther; 2011 Nov; 18(6):e197-201. PubMed ID: 20393344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
    Rupp H; Zarain-Herzberg A; Maisch B
    Herz; 2002 Nov; 27(7):621-36. PubMed ID: 12439634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment.
    Lee L; Horowitz J; Frenneaux M
    Eur Heart J; 2004 Apr; 25(8):634-41. PubMed ID: 15084367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic agents in the management of diabetic coronary patients: a new era.
    Marazzi G; Volterrani M; Rosano GM
    Int J Cardiol; 2008 Jun; 127(1):124-5. PubMed ID: 18199501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic support for the heart: complementary therapy for heart failure?
    Heggermont WA; Papageorgiou AP; Heymans S; van Bilsen M
    Eur J Heart Fail; 2016 Dec; 18(12):1420-1429. PubMed ID: 27813339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The metabolic treatment of coronary artery disease and heart failure.
    Di Napoli P
    Curr Pharm Des; 2009; 15(8):826. PubMed ID: 19275645
    [No Abstract]   [Full Text] [Related]  

  • 7. Metabolic therapeutics in angina pectoris: history revisited with perhexiline.
    Inglis S; Stewart S
    Eur J Cardiovasc Nurs; 2006 Jun; 5(2):175-84. PubMed ID: 16469541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic agents in the management of diabetic coronary patients: a new era.
    Celik T; Kursaklioglu H; Iyisoy A; Jata B
    Int J Cardiol; 2008 Jun; 127(1):133-4. PubMed ID: 17561287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of myocardial metabolism: an emerging therapeutic principle.
    Horowitz JD; Chirkov YY; Kennedy JA; Sverdlov AL
    Curr Opin Cardiol; 2010 Jul; 25(4):329-34. PubMed ID: 20535068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle.
    Fang YH; Piao L; Hong Z; Toth PT; Marsboom G; Bache-Wiig P; Rehman J; Archer SL
    J Mol Med (Berl); 2012 Jan; 90(1):31-43. PubMed ID: 21874543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic modulation and optimization of energy consumption in heart failure.
    Ferrari R; Cicchitelli G; Merli E; Andreadou I; Guardigli G
    Med Clin North Am; 2003 Mar; 87(2):493-507, xii-xiii. PubMed ID: 12693736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of long-chain fatty acid metabolism does not affect platelet aggregation responses.
    Willoughby SR; Chirkov YY; Kennedy JA; Murphy GA; Chirkova LP; Horowitz JD
    Eur J Pharmacol; 1998 Sep; 356(2-3):207-13. PubMed ID: 9774251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
    MacInnes A; Fairman DA; Binding P; Rhodes Ja; Wyatt MJ; Phelan A; Haddock PS; Karran EH
    Circ Res; 2003 Aug; 93(3):e26-32. PubMed ID: 12869391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure.
    Fragasso G; Salerno A; Lattuada G; Cuko A; Calori G; Scollo A; Ragogna F; Arioli F; Bassanelli G; Spoladore R; Luzi L; Margonato A; Perseghin G
    Heart; 2011 Sep; 97(18):1495-500. PubMed ID: 21700755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Metabolic therapy for heart failure].
    Loiacono F; Alberti L; Lauretta L; Puccetti P; Silipigni C; Margonato A; Fragasso G
    Recenti Prog Med; 2014; 105(7-8):288-94. PubMed ID: 25072544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac metabolism as a target for the treatment of heart failure.
    Taegtmeyer H
    Circulation; 2004 Aug; 110(8):894-6. PubMed ID: 15326079
    [No Abstract]   [Full Text] [Related]  

  • 17. The adrenergic-fatty acid load in heart failure.
    Opie LH; Knuuti J
    J Am Coll Cardiol; 2009 Oct; 54(18):1637-46. PubMed ID: 19850204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatty acid oxidation inhibition with PPARalpha activation (FOXIB/PPARalpha) for normalizing gene expression in heart failure?
    Rupp H; Rupp TP; Maisch B
    Cardiovasc Res; 2005 Jun; 66(3):423-6. PubMed ID: 15914105
    [No Abstract]   [Full Text] [Related]  

  • 19. Metabolic therapy of heart failure.
    Fragasso G; Salerno A; Spoladore R; Bassanelli G; Arioli F; Margonato A
    Curr Pharm Des; 2008; 14(25):2582-91. PubMed ID: 18991675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Metabolism and the hypertrophied heart of the elderly].
    Rupp H; Rupp TP; Maisch B
    Dtsch Med Wochenschr; 2005 Mar; 130(12):726-30. PubMed ID: 15776359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.